AU2010306830C1 - Novel mek inhibitors, useful in the treatment of diseases - Google Patents

Novel mek inhibitors, useful in the treatment of diseases Download PDF

Info

Publication number
AU2010306830C1
AU2010306830C1 AU2010306830A AU2010306830A AU2010306830C1 AU 2010306830 C1 AU2010306830 C1 AU 2010306830C1 AU 2010306830 A AU2010306830 A AU 2010306830A AU 2010306830 A AU2010306830 A AU 2010306830A AU 2010306830 C1 AU2010306830 C1 AU 2010306830C1
Authority
AU
Australia
Prior art keywords
compound
formula
mmol
solvate
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2010306830A
Other languages
English (en)
Other versions
AU2010306830A1 (en
AU2010306830B2 (en
Inventor
Mahendra Devichand Chordia
Uday R. Khire
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allomek Therapeutics LLC
Original Assignee
Allomek Therapeutics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allomek Therapeutics LLC filed Critical Allomek Therapeutics LLC
Publication of AU2010306830A1 publication Critical patent/AU2010306830A1/en
Application granted granted Critical
Publication of AU2010306830B2 publication Critical patent/AU2010306830B2/en
Assigned to ALLOMEK THERAPEUTICS LLC reassignment ALLOMEK THERAPEUTICS LLC Amend patent request/document other than specification (104) Assignors: ALLOSTEM THERAPEUTICS LLC
Publication of AU2010306830C1 publication Critical patent/AU2010306830C1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D291/00—Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms
    • C07D291/08—Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AU2010306830A 2009-10-13 2010-10-13 Novel mek inhibitors, useful in the treatment of diseases Active AU2010306830C1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25093609P 2009-10-13 2009-10-13
US61/250,936 2009-10-13
PCT/US2010/052514 WO2011047055A2 (en) 2009-10-13 2010-10-13 Novel mek inhibitors, useful in the treatment of diseases

Publications (3)

Publication Number Publication Date
AU2010306830A1 AU2010306830A1 (en) 2012-05-31
AU2010306830B2 AU2010306830B2 (en) 2014-11-06
AU2010306830C1 true AU2010306830C1 (en) 2015-05-28

Family

ID=43876849

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2010306830A Active AU2010306830C1 (en) 2009-10-13 2010-10-13 Novel mek inhibitors, useful in the treatment of diseases

Country Status (10)

Country Link
US (1) US9034861B2 (https=)
EP (1) EP2488507B1 (https=)
JP (1) JP5892612B2 (https=)
KR (1) KR20120094165A (https=)
CN (1) CN102666512B (https=)
AU (1) AU2010306830C1 (https=)
BR (1) BR112012008599A2 (https=)
CA (1) CA2814617C (https=)
ES (1) ES2534358T3 (https=)
WO (1) WO2011047055A2 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190008859A1 (en) 2015-08-21 2019-01-10 Acerta Pharma B.V. Therapeutic Combinations of a MEK Inhibitor and a BTK Inhibitor
AU2018319344B2 (en) 2017-08-23 2024-04-04 Cell Receptor AG Combination of a MAPK/ERK pathway inhibitor and a glycosaminoglycan for the treatment of cancer
US20220143049A1 (en) 2019-03-21 2022-05-12 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
EP4054579A1 (en) 2019-11-08 2022-09-14 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
MX2023006434A (es) * 2020-12-16 2023-06-13 Abm Therapeutics Corp Inhibidores de quinasa y usos de los mismos.
EP4346826A4 (en) 2021-05-27 2025-04-30 Mirati Therapeutics, Inc. COMBINATION THERAPIES
WO2025073765A1 (en) 2023-10-03 2025-04-10 Institut National de la Santé et de la Recherche Médicale Methods of prognosis and treatment of patients suffering from melanoma
WO2025147497A1 (en) 2024-01-05 2025-07-10 Pasithea Therapeutics Corp. Solid forms comprising (5r,6s)-10,11-difluoro-12-((2-fluoro-4-iodophenyl)amino)-5,6-dihydroxy-4,5,6,7-tetrahydro-1h-spiro[benzo[b][1,5,4]oxathiazecine-3,1'-cyclopropane] 2,2-dioxide, and compositions comprising and methods of using the same
WO2025147503A1 (en) 2024-01-05 2025-07-10 Pasithea Therapeutics Corp. 10,11-difluoro-12-((2-fluoro-4-iodophenyl)amino)-5,6-dihydroxy-4,5,6,7-tetrahydro-1h-spiro[benzo[b][1,5,4]oxathiazecine-3,1'-cyclopropane] 2,2-dioxide stereoisomers, and compositions comprising and methods of using the same

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007014011A2 (en) * 2005-07-21 2007-02-01 Ardea Biosciences, Inc. N-(arylamino)-sulfonamide inhibitors of mek

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8827305D0 (en) 1988-11-23 1988-12-29 British Bio Technology Compounds
US5455258A (en) 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
US5863949A (en) 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
DK0821671T3 (da) 1995-04-20 2001-04-23 Pfizer Arylsulfonylhydroxamsyrederivater som MMP- og TNF-inhibitorer
DE69624081T2 (de) 1995-12-20 2003-06-12 Agouron Pharmaceuticals, Inc. Matrix-metalloprotease Inhibitoren
EP0818442A3 (en) 1996-07-12 1998-12-30 Pfizer Inc. Cyclic sulphone derivatives as inhibitors of metalloproteinases and of the production of tumour necrosis factor
EP0923585B1 (en) 1996-07-18 2002-05-08 Pfizer Inc. Phosphinate based inhibitors of matrix metalloproteases
WO1998007697A1 (en) 1996-08-23 1998-02-26 Pfizer Inc. Arylsulfonylamino hydroxamic acid derivatives
WO1998030566A1 (en) 1997-01-06 1998-07-16 Pfizer Inc. Cyclic sulfone derivatives
EP0977733B1 (en) 1997-02-03 2003-09-03 Pfizer Products Inc. Arylsulfonylamino hydroxamic acid derivatives
JP2000507975A (ja) 1997-02-07 2000-06-27 ファイザー・インク Ｎ−ヒドロキシ−β−スルホニルプロピオンアミド誘導体類及びそれらのマトリックスメタロプロテイナーゼ阻害薬としての使用
EA002546B1 (ru) 1997-02-11 2002-06-27 Пфайзер Инк. Производные арилсульфонилгидроксамовой кислоты
AU730248B2 (en) 1997-08-08 2001-03-01 Pfizer Products Inc. Aryloxyarylsulfonylamino hydroxamic acid derivatives
GB9725782D0 (en) 1997-12-05 1998-02-04 Pfizer Ltd Therapeutic agents
GB9801690D0 (en) 1998-01-27 1998-03-25 Pfizer Ltd Therapeutic agents
PA8469401A1 (es) 1998-04-10 2000-05-24 Pfizer Prod Inc Derivados biciclicos del acido hidroxamico
PA8469501A1 (es) 1998-04-10 2000-09-29 Pfizer Prod Inc Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico
DK1004578T3 (da) 1998-11-05 2004-06-28 Pfizer Prod Inc 5-oxo-pyrrolidin-2-carboxylsyrehydroxamidderivater
GB9912961D0 (en) 1999-06-03 1999-08-04 Pfizer Ltd Metalloprotease inhibitors
GB0131034D0 (en) * 2001-12-28 2002-02-13 Pharmacia & Upjohn Spa Benzocyclodecane derivatives with antitumor activity
EP1467968A1 (en) * 2002-01-23 2004-10-20 Warner-Lambert Company LLC N-(4-substituted phenyl)-anthranilic acid hydroxamate esters
MY144232A (en) * 2004-07-26 2011-08-15 Chugai Pharmaceutical Co Ltd 5-substituted-2-phenylamino benzamides as mek inhibitors
US7429667B2 (en) 2005-01-20 2008-09-30 Ardea Biosciences, Inc. Phenylamino isothiazole carboxamidines as MEK inhibitors
US8101799B2 (en) 2005-07-21 2012-01-24 Ardea Biosciences Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK
SI1912636T1 (sl) 2005-07-21 2014-08-29 Ardea Biosciences, Inc. N-(arilamino)-sulfonamidni inhibitorji MEK
WO2009018233A1 (en) 2007-07-30 2009-02-05 Ardea Biosciences, Inc. Derivatives of n-(arylamino) sulfonamides including polymorphs as inhibitors of mek as well as compositions, methods of use and methods for preparing the same
US7842836B2 (en) 2006-04-11 2010-11-30 Ardea Biosciences N-aryl-N'alkyl sulfamides as MEK inhibitors
MX2008013097A (es) 2006-04-18 2008-10-27 Ardea Biosciences Inc Piridona sulfonamidas y piridona sulfamidas como inhibidores de metiletilcetona.
MX2009007661A (es) 2007-01-19 2009-12-14 Ardea Biosciences Inc Inhibidores de mek.
UA99731C2 (ru) 2007-07-30 2012-09-25 Ардеа Биосайенсис, Инк Кристаллические полиморфные формы n-(ариламино)сульфонамидов как ингибиторы мэк, композиция (варианты) и применение
CA2696977C (en) 2007-10-16 2012-12-04 Pharmathen S.A. Improved pharmaceutical composition containing a pyrrolidone anticonvulsant agent and method for the preparation thereof
US8044240B2 (en) 2008-03-06 2011-10-25 Ardea Biosciences Inc. Polymorphic form of N-(S)-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide and uses thereof
US8808742B2 (en) * 2008-04-14 2014-08-19 Ardea Biosciences, Inc. Compositions and methods for preparing and using same
CN102134218A (zh) 2009-06-15 2011-07-27 凯美隆(北京)药业技术有限公司 6-芳氨基吡啶酮磺酰胺和6-芳氨基吡嗪酮磺酰胺mek抑制剂

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007014011A2 (en) * 2005-07-21 2007-02-01 Ardea Biosciences, Inc. N-(arylamino)-sulfonamide inhibitors of mek

Also Published As

Publication number Publication date
JP5892612B2 (ja) 2016-03-23
AU2010306830A1 (en) 2012-05-31
WO2011047055A2 (en) 2011-04-21
US9034861B2 (en) 2015-05-19
JP2013507453A (ja) 2013-03-04
ES2534358T3 (es) 2015-04-21
CN102666512A (zh) 2012-09-12
WO2011047055A3 (en) 2011-08-18
EP2488507A4 (en) 2013-05-01
EP2488507B1 (en) 2014-12-17
BR112012008599A2 (pt) 2019-09-24
KR20120094165A (ko) 2012-08-23
EP2488507A2 (en) 2012-08-22
AU2010306830B2 (en) 2014-11-06
WO2011047055A8 (en) 2012-05-24
CA2814617A1 (en) 2011-04-21
CA2814617C (en) 2017-12-19
CN102666512B (zh) 2014-11-26
US20120208859A1 (en) 2012-08-16

Similar Documents

Publication Publication Date Title
AU2010306830C1 (en) Novel mek inhibitors, useful in the treatment of diseases
US8044240B2 (en) Polymorphic form of N-(S)-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide and uses thereof
EP2012786B1 (en) Pyridone sulfonamides and pyridone sulfamides as mek inhibitors
US7842836B2 (en) N-aryl-N'alkyl sulfamides as MEK inhibitors
AU2008282338B2 (en) Derivatives of N-(arylamino) sulfonamides including polymorphs as inhibitors of MEK as well as compositions, methods of use and methods for preparing the same
EP2411366B1 (en) Dihydropyridin sulfonamides and dihydropyridin sulfamides as mek inhibitors
AU2009236325A1 (en) Compositions and methods for preparing and using same
US20150250762A1 (en) Novel mek inhibitors for treating cardiomyopathies and related conditions
HK1174619A (en) Novel mek inhibitors, useful in the treatment of diseases
HK1128617B (en) Pyridone sulfonamides and pyridone sulfamides as mek inhibitors

Legal Events

Date Code Title Description
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 15 JAN 2015 .

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 15 JAN 2015

FGA Letters patent sealed or granted (standard patent)